[Form 4] Nautilus Biotechnology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Nautilus Biotechnology director Matthew S. McIlwain received a grant of stock options for 45,000 shares of common stock. These options have an exercise price of $2.28 per share and expire on June 18, 2036. Following this grant, he holds options for 45,000 shares directly.

The options were awarded as compensation, not purchased in the open market, and vest over time. One-twelfth of the options vest each month after the grant date as long as he continues to serve as a qualifying service provider to the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider McIlwain Matthew S

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	45,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 45,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 45,000 options Exercise price: $2.28 per share Expiration date: June 18, 2036 +2 more

5 metrics

Options granted 45,000 options Stock Option (Right to Buy) grant to director

Exercise price $2.28 per share Conversion/exercise price of option grant

Expiration date June 18, 2036 Option grant expiry

Post-grant option holdings 45,000 options Total options following transaction

Vesting schedule 1/12 monthly One-twelfth vests each month after grant date

Key Terms

Stock Option (Right to Buy), 2021 Equity Incentive Plan, Service Provider, Grant, award, or other acquisition

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

2021 Equity Incentive Plan financial

"as defined in the the Issuer's 2021 Equity Incentive Plan"

Service Provider financial

"continuous status as a "Service Provider" through each applicable vesting date"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 04:14 PM Accepted by SEC EDGAR 06/22/2026 - 04:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McIlwain Matthew S

(Last) (First) (Middle)

C/O NAUTILUS BIOTECHNOLOGY, INC.

2701 EASTLAKE AVE. E.

(Street)

SEATTLE WASHINGTON 98102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nautilus Biotechnology, Inc. [ NAUT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.28	06/18/2026		A		45,000		(1)	06/18/2036	Common Stock	45,000	$0	45,000	D

Explanation of Responses:

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Remarks:

	/s/ Matthew B. Murphy, as Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)